Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.39% | 1.81% | 1.87% | 1.10% | -1.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.39% | 1.81% | 1.87% | 1.10% | -1.33% |
| Cost of Revenue | 4.56% | 4.24% | 9.65% | 10.12% | 9.13% |
| Gross Profit | -0.24% | 0.59% | -1.83% | -3.00% | -5.96% |
| SG&A Expenses | 1.04% | -0.55% | -0.87% | -1.00% | -2.40% |
| Depreciation & Amortization | 0.09% | -0.31% | 0.14% | -0.64% | -4.74% |
| Other Operating Expenses | -70.58% | 84.79% | -64.97% | -128.28% | -51.84% |
| Total Operating Expenses | 0.24% | 1.19% | 0.27% | -0.07% | 1.09% |
| Operating Income | 10.12% | 6.45% | 13.89% | 8.61% | -16.52% |
| Income Before Tax | 328.54% | 177.19% | 39.74% | 23.08% | -88.07% |
| Income Tax Expenses | 153.11% | 172.80% | 194.75% | -465.40% | -269.48% |
| Earnings from Continuing Operations | -1.61% | -30.01% | 7.55% | 37.69% | -55.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -17.00% | -58.04% | -60.63% | -70.50% | -538.31% |
| Net Income | -1.63% | -30.09% | 7.52% | 37.67% | -55.27% |
| EBIT | 10.12% | 6.45% | 13.89% | 8.61% | -16.52% |
| EBITDA | 3.96% | 1.88% | 6.12% | 4.77% | -7.10% |
| EPS Basic | -1.48% | -30.61% | 6.34% | 35.82% | -55.73% |
| Normalized Basic EPS | 12.47% | 10.94% | 36.42% | 21.98% | -15.03% |
| EPS Diluted | -3.07% | -32.06% | 5.32% | 35.82% | -55.75% |
| Normalized Diluted EPS | 11.55% | 9.86% | 35.28% | 21.38% | -14.95% |
| Average Basic Shares Outstanding | 0.69% | 0.99% | 1.00% | 0.97% | 0.87% |
| Average Diluted Shares Outstanding | 1.17% | 1.57% | 1.58% | 1.29% | 0.59% |
| Dividend Per Share | 1.44% | 1.44% | -2.89% | -2.89% | -3.60% |
| Payout Ratio | 0.09% | 0.40% | -0.10% | -0.30% | 1.15% |